GLOBUS MEDICAL INC GMED

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived NYSE

Globus Medical, Inc. (together, as applicable, with its consolidated subsidiaries, "Globus," the "Company," "we," "us" or "our"), headquartered in Audubon, Pennsylvania, is a medical device company that develops and commercializes healthcare solutions whose mission is to improve the quality of life of patients with musculoskeletal disorders. Founded in 2003, Globus is committed to medical device innovation and delivering exceptional service to hospitals, ambulatory surgery centers and physicians to advance patient care and improve efficiency. Since inception, Globus has listened to the voice of the surgeon to develop practical solutions and products to help surgeons effectively treat patients and improve lives.

Last close 81.83 2026-10-26
Market cap $10.99B 2026-06-30 share count
52-week range 59.51 - 101.40

Valuation FY2025 figures against the last close

P/S3.7x
P/E20.9x
P/FCF18.7x
EV/EBITDA14.5x
Dividend yield—
Diluted EPS3.92

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $2.94B$2.52B$1.57B$1.02B$958.1M$789.0M$785.4M$713.0M$636.0M$564.0M
Cost of revenue $957.8M$1.04B$548.2M$263.7M$239.2M$217.5M$180.0M$159.4M$150.5M$134.7M
Gross profit $1.98B$1.48B$1.02B$759.1M$718.9M$571.6M$605.4M$553.6M$485.5M$429.3M
R&D $147.2M$163.8M$124.0M$73.0M$97.3M$84.5M$60.1M$55.5M$43.7M$44.5M
SG&A $1.18B$981.4M$643.8M$432.1M$408.1M$354.8M$354.8M$311.6M$267.8M$222.2M
Total operating expenses ——$887.2M$531.2M$546.9M$460.1M$433.4M$384.2M$323.7M$275.1M
Operating income $479.8M$166.0M$133.1M$228.0M$172.0M$111.4M$172.0M$169.3M$161.8M$154.1M
Interest expense —$4.2M$20.1M$14.2M$9.3M$14.0M$17.4M$13.3M$6.6M$3.1M
Pre-tax income $605.1M$120.7M$165.4M$243.0M$180.4M$125.9M$189.9M$188.6M$169.9M$157.3M
Income tax $67.2M$17.7M$42.5M$52.9M$31.2M$23.6M$34.7M$32.1M$62.6M$52.9M
Net income $537.9M$103.0M$122.9M$190.2M$149.2M$102.3M$155.2M$156.5M$107.3M$104.3M
EPS, basic 3.980.761.091.891.481.041.571.601.121.09
EPS, diluted 3.920.751.071.851.441.011.521.541.101.08
Shares, diluted (wtd. avg.) 137.1M137.9M114.6M102.6M103.6M101.0M102.0M101.3M97.9M96.4M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $526.2M$784.4M$467.3M$150.5M$193.1M$239.4M$195.7M$139.7M$118.8M$67.0M
Short-term investments $31.1M$105.6M$50.5M$295.6M$250.4M$187.3M$115.8M$199.9M——
Receivables $678.9M$557.7M$503.2M$213.2M$164.4M$141.7M$154.3M$137.1M$116.7M$92.0M
Inventory $759.3M$659.2M$848.1M$299.0M$237.0M$229.2M$196.3M$131.3M$108.4M$112.7M
Total current assets $2.13B$2.18B$1.92B$983.3M$864.5M$821.8M$687.5M$630.7M$620.3M$513.8M
Property, plant and equipment $564.5M$561.9M$586.9M$243.7M$221.1M$216.9M$199.8M$171.9M$143.2M$124.2M
Goodwill $1.44B$1.43B$1.43B$197.5M$179.7M$156.7M$128.8M$123.7M$123.9M$105.9M
Other intangibles $745.1M$795.1M$924.6M$63.6M$68.7M$86.9M$78.8M$87.3M$78.7M$61.7M
Total assets $5.30B$5.25B$5.09B$2.08B$1.96B$1.68B$1.53B$1.30B$1.08B$927.6M
Accounts payable $98.9M$75.1M$56.7M$36.1M$22.0M$18.2M$24.6M$25.9M$25.0M$17.5M
Total current liabilities $498.5M$855.9M$392.3M$159.2M$140.2M$120.8M$111.4M$96.1M$93.1M$79.9M
Total liabilities $729.5M$1.07B$1.09B$229.8M$215.9M$173.2M$129.6M$115.2M$110.7M$95.6M
Retained earnings $1.39B$1.15B$1.14B$1.24B$1.19B$1.05B$1.05B$892.7M$736.2M$628.9M
Total equity $4.57B$4.18B$4.00B$1.85B$1.74B$1.51B$1.40B$1.19B$967.8M$832.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $753.4M$520.6M$243.5M$178.5M$276.3M$198.8M$172.0M$181.6M$159.1M$147.8M
Depreciation and amortisation $276.8M$253.4M$145.5M$68.3M$69.9M$62.9M$52.7M$41.6M$42.1M$38.8M
Stock-based compensation $49.8M$54.2M$52.7M$32.8M$30.6M$27.1M$26.1M$21.9M$14.7M$11.4M
Capital expenditure $164.7M$115.4M$78.3M$74.0M$56.9M$63.7M$70.8M$59.7M$51.3M$40.9M
Investing cash flow -$355.0M-$176.1M$303.0M-$110.4M-$375.9M-$117.3M-$140.3M-$193.0M-$111.3M-$162.7M
Financing cash flow -$679.2M-$27.7M-$231.8M-$110.0M$54.1M-$38.7M$24.4M$32.6M$1.6M$470.0K
Buybacks $300.5M$85.8M$225.6M$144.5M—$104.7M————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-027196.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 1B 2B 3B Revenue, FY2016: 564M Gross profit, FY2016: 429.3M Net income, FY2016: 104.3M Revenue, FY2017: 636M Gross profit, FY2017: 485.5M Net income, FY2017: 107.3M Revenue, FY2018: 713M Gross profit, FY2018: 553.6M Net income, FY2018: 156.5M Revenue, FY2019: 785.4M Gross profit, FY2019: 605.4M Net income, FY2019: 155.2M Revenue, FY2020: 789M Gross profit, FY2020: 571.6M Net income, FY2020: 102.3M Revenue, FY2021: 958.1M Gross profit, FY2021: 718.9M Net income, FY2021: 149.2M Revenue, FY2022: 1B Gross profit, FY2022: 759.1M Net income, FY2022: 190.2M Revenue, FY2023: 1.6B Gross profit, FY2023: 1B Net income, FY2023: 122.9M Revenue, FY2024: 2.5B Gross profit, FY2024: 1.5B Net income, FY2024: 103M Revenue, FY2025: 2.9B Gross profit, FY2025: 2B Net income, FY2025: 537.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $564.0M $636.0M $713.0M $785.4M $789.0M $958.1M $1.02B $1.57B $2.52B $2.94B
Gross profit $429.3M $485.5M $553.6M $605.4M $571.6M $718.9M $759.1M $1.02B $1.48B $1.98B
Net income $104.3M $107.3M $156.5M $155.2M $102.3M $149.2M $190.2M $122.9M $103.0M $537.9M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.42B 36.4x 11.2%
MMM 3M CO $89.11B 28.8x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.06B 23.5x 19.9%
BDX BECTON DICKINSON & CO $53.49B 33.7x 8.2%
RMD RESMED INC $36.52B 24.3x 9.9%
DXCM DEXCOM INC $29.65B 37.6x 15.6%
MDLN Medline Inc. $28.86B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.78B 58.1x 6.3%